H K Olberg1,2, G E Eide3,4, R J Cox5,6,7, Å Jul-Larsen6,7, S L Lartey5,6,7, C A Vedeler1,2,8, K-M Myhr8,9. 1. Department of Neurology, Haukeland University Hospital, Bergen, Norway. 2. Department of Clinical Medicine, University of Bergen, Bergen, Norway. 3. Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway. 4. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 5. Department of Research and Development, Haukeland University Hospital, Bergen, Norway. 6. Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway. 7. KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Bergen, Norway. 8. KG Jebsen Centre for MS Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway. 9. Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Abstract
BACKGROUND AND PURPOSE: We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared with healthy controls. METHODS: Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared with 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre-vaccination and 3, 6 and 12 months post-vaccination. The vaccine responses were evaluated by the hemagglutination inhibition assay and adjusted for age and gender. RESULTS: No significant differences in rates of protection against H1N1 for interferon beta-1a/1b and glatiramer acetate were observed as compared with controls at 3, 6 and 12 months. Fingolimod provided reduced protection at all time points post-vaccination, whereas natalizumab displayed reduced protection at 3 and 6 months. Patients without immunomodulation did not display protection rates that were significantly different from the controls at 3 and 12 months. CONCLUSION: These findings suggest that patients with multiple sclerosis receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza-specific vaccine responses.
BACKGROUND AND PURPOSE: We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared with healthy controls. METHODS: Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared with 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre-vaccination and 3, 6 and 12 months post-vaccination. The vaccine responses were evaluated by the hemagglutination inhibition assay and adjusted for age and gender. RESULTS: No significant differences in rates of protection against H1N1 for interferon beta-1a/1b and glatiramer acetate were observed as compared with controls at 3, 6 and 12 months. Fingolimod provided reduced protection at all time points post-vaccination, whereas natalizumab displayed reduced protection at 3 and 6 months. Patients without immunomodulation did not display protection rates that were significantly different from the controls at 3 and 12 months. CONCLUSION: These findings suggest that patients with multiple sclerosis receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza-specific vaccine responses.
Authors: Amit Bar-Or; Jonathan C Calkwood; Cathy Chognot; Joanna Evershed; Edward J Fox; Ann Herman; Marianna Manfrini; John McNamara; Derrick S Robertson; Daniela Stokmaier; Jeanette K Wendt; Kevin L Winthrop; Anthony Traboulsee Journal: Neurology Date: 2020-07-29 Impact factor: 9.910
Authors: Christoph Metze; Alexander Winkelmann; Micha Loebermann; Michael Hecker; Brunhilde Schweiger; Emil Christian Reisinger; Uwe Klaus Zettl Journal: CNS Neurosci Ther Date: 2018-07-25 Impact factor: 5.243